Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,892 followers.

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma #lymphoma #lymsm https://t.co/VH8lOK0R8k

21 Dec 2021

Reply Repost Favourite

New article: Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma https://t.co/cYpz2SJ6ym #FL #lymsm #hematology https://t.co/X3f6SNCug9

20 Dec 2021

Reply Repost Favourite

New research: Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma: The key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving… https://t.co/Zu

03 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.